CCR8 and neoplasm: Allowing the radiolabeled antibody to reach its highest uptake in the tumor before giving immunotherapy will allow for more profound killing of CCR8+ Tregs in the tumor before CD8+ T cells and other immune cells will start coming into the tumor microenvironment [21].